STOP TB Partnership and Sabin Representatives
Share key findings from the joint Sabin Vaccine Institute and STOP TB Partnership survey on TB vaccine readiness, highlighting perspectives from both the TB and immunization communities across countries and regions. The discussion will explore current levels of preparedness, perceived challenges and opportunities for future TB vaccine introduction, and the importance of cross-sector collaboration as next-generation TB vaccines continue to advance.
Dr. Alemnew Dagnew, Gates MRI
Dr. Dagnew will provide an overview of the M72 TB vaccine candidate and its potential implications for the future of tuberculosis prevention globally. The session will explore recent progress in clinical development, the significance of ongoing investments and partnerships, and what countries, immunization programs, and global health stakeholders should begin considering as preparations for potential vaccine introduction advance.
Dr. Rolando Pajon, Biofabri
Dr. Pajon will share insights on Mtbvac and its role within the evolving TB vaccine pipeline. His presentation will highlight the scientific approach behind the candidate, recent progress in development, and key considerations for future implementation and access as the global health community prepares for next-generation TB vaccines.